Adverse event: treatment‐related mortality · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP showed no clear difference in adverse event: treatment‐related mortality compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: secondary malignancies · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP showed no clear difference in adverse event: secondary malignancies compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: secondary malignancies: AML or MDS · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP may leads to higher adverse event: secondary malignancies: AML or MDS compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: infertility (secondary amenorrhoea) · Patients with early unfavourable or advanced stage HL
It is very uncertain whether escalated BEACOPP changes adverse event: infertility (secondary amenorrhoea) compared with chemotherapy including ABVD (very low certainty).
1 finding from 1 review
Quality of life · Patients with early unfavourable or advanced stage HL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone may leads to lower secondary malignant neoplasms compared with same chemotherapy plus radiotherapy (low certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)
Fewer showed no clear difference in secondary malignant neoplasms compared with more courses of chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Fewer showed no clear difference in death compared with more courses of chemotherapy (with or without radiotherapy (high certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)
Fewer showed no clear difference in progression/relapse compared with more courses of chemotherapy (with or without radiotherapy (high certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy showed no clear difference in secondary malignant neoplasms compared with ABVD‐like chemotherapy (with or without radiotherapy (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy showed no clear difference in death compared with ABVD‐like chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy probably leads to lower progression/relapse compared with ABVD‐like chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in death compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in progression/relapse compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus extended‐field radiation (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in death compared with same chemotherapy plus extended‐field radiation (high certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in progression/relapse compared with same chemotherapy plus extended‐field radiation (high certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus lower‐dose radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus higher‐dose radiation (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus lower‐dose radiation showed no clear difference in death compared with same chemotherapy plus higher‐dose radiation (high certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus lower‐dose radiation showed no clear difference in progression/relapse compared with same chemotherapy plus higher‐dose radiation (high certainty).
1 finding from 1 review